Drug Trial Radar · NCT00358501
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Jul 2006
Primary completion
Sep 2008
Study completion Mar 2015
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- FDA Office of Orphan Products Development
- First posted
- Aug 1, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis of blood samples.
Conditions
- Severe Hepatic Veno-Occlusive Disease
Interventions
DefibrotideDrug
Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival at Day+100 Following Hematopoietic Stem Cell TransplantTime frame: Day+100 post hematopoietic stem cell transplant
- Complete Response by Day+100 Post Hematopoietic Stem Cell TransplantTime frame: Day+100 post hematopoietic stem cell transplant
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Duarte, California
Site not named
Palo Alto, California
Site not named
Denver, Colorado
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Maywood, Illinois
Site not named
Indianapolis, Indiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Rochester, Minnesota
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Hackensack, New Jersey
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Site not named
Seattle, Washington
Site not named
Vancouver, British Columbia, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.